These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 10373061

  • 21. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.
    Locatelli F, Pession A, Bonetti F, Maserati E, Prete L, Pedrazzoli P, Zecca M, Prete A, Paolucci P, Cazzola M.
    Leukemia; 1994 May; 8(5):844-9. PubMed ID: 8182940
    [Abstract] [Full Text] [Related]

  • 22. Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institution.
    Sanz GF, Saavedra S, Jiménez C, Senent L, Cervera J, Planelles D, Bolufer P, Larrea L, Martín G, Martínez J, Jarque I, Moscardó F, Plumé G, Andreu R, de la Rubia J, Barragán E, Solves P, Soler MA, Sanz MA.
    Bone Marrow Transplant; 2001 Apr; 27(7):693-701. PubMed ID: 11360108
    [Abstract] [Full Text] [Related]

  • 23. [Therapeutic efficacy of hematopoietic stem cell transplantation in patients with chronic myelogenous leukemia].
    Liu QF, Fan ZP, Sun J, Zhang Y, Liu XL, Xu D, Xu B, Feng R, Meng FY, Zhou SY.
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Nov; 24(11):1227-9, 1241. PubMed ID: 15567763
    [Abstract] [Full Text] [Related]

  • 24. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.
    Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB.
    Biol Blood Marrow Transplant; 1999 Nov; 5(5):306-15. PubMed ID: 10534061
    [Abstract] [Full Text] [Related]

  • 25. Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update.
    Brodsky I, Biggs JC, Szer J, Crilley P, Atkinson K, Downs K, Dodds A, Concannon AJ, Avalos BR, Tutschka P.
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):27-31; quiz 32. PubMed ID: 8342072
    [Abstract] [Full Text] [Related]

  • 26. Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors.
    Bishop MR, Henslee-Downey PJ, Anderson JR, Romond EH, Marciniak E, Yankey R, Reeves M, Thompson JS.
    Bone Marrow Transplant; 1996 Oct; 18(4):747-53. PubMed ID: 8899190
    [Abstract] [Full Text] [Related]

  • 27. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C, Regazzi E, Andrizzi C, Savoldo B, Garau D, Montefusco E, Vignetti M, Mandelli F, Rizzoli V, Meloni G.
    Haematologica; 1997 Oct; 82(3):291-6. PubMed ID: 9234574
    [Abstract] [Full Text] [Related]

  • 28. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH, Huang XJ, Liu KY, Xu LP, Liu DH, Chen H, Chen YH, Wang JZ, Han W, Lu DP.
    Chin Med J (Engl); 2007 Mar 20; 120(6):463-8. PubMed ID: 17439737
    [Abstract] [Full Text] [Related]

  • 29. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan 20; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 30. [Allogeneic bone marrow transplantation in chronic myeloid leukemia. The clinical results and risk factors in 70 patients].
    Tomás JF, Peñarrubia MJ, García JA, Figuera A, Gómez-García de Soria V, Steegmann JL, Arranz R, Cámara R, Gabriel R, Vázquez L.
    Med Clin (Barc); 1995 Nov 11; 105(16):605-11. PubMed ID: 8523939
    [Abstract] [Full Text] [Related]

  • 31. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR.
    Bone Marrow Transplant; 2000 Oct 11; 26(7):711-6. PubMed ID: 11042650
    [Abstract] [Full Text] [Related]

  • 32. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
    Saikia TK, Parikh PM, Tawde S, Amare-Kadam PS, Rajadhyaksha S, Chhaya S.
    Natl Med J India; 2004 Oct 11; 17(2):71-3. PubMed ID: 15141598
    [Abstract] [Full Text] [Related]

  • 33. [The toxicity of busulphan and cyclophosphamide as the preparative regimen for allogeneic peripheral blood stem cell transplantation].
    Zhu K, Xu Y, Wu D, Xu X, Huang L.
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug 11; 21(8):403-5. PubMed ID: 11877010
    [Abstract] [Full Text] [Related]

  • 34. The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy.
    Copelan EA, Penza SL, Theil KS, Elder PJ, Bechtel TP, Tighe MB, Ezzone SA, Scholl MD, Belt PS, Young DC, Avalos BR.
    Bone Marrow Transplant; 2000 Nov 11; 26(10):1037-43. PubMed ID: 11108300
    [Abstract] [Full Text] [Related]

  • 35. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ, Li J, Tan EX, Zhang GC, Wu XY, Peng AH, Zheng D, Zou WY, Hong WD, Luo SK.
    Zhonghua Zhong Liu Za Zhi; 2006 Jul 11; 28(7):545-8. PubMed ID: 17147125
    [Abstract] [Full Text] [Related]

  • 36. [Allogeneic bone marrow transplantation in myeloid leukemia: chemical conditioning, clinical course and results].
    Glejzer O, Sedzimirska M, Tomaszewska-Toporska B, Tomeczko J, Kołodziej J, Pacuszko T, Was A, Bocheńska J, Jaźwiec B, Klimczak A.
    Acta Haematol Pol; 1992 Jul 11; 23(2 Suppl 1):49-59. PubMed ID: 1488872
    [Abstract] [Full Text] [Related]

  • 37. High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia.
    Kantarjian HM, Talpaz M, Andersson B, Khouri I, Giralt S, Rios MB, Champlin R, Hester J, Deisseroth AB.
    Bone Marrow Transplant; 1994 Jul 11; 14(1):57-61. PubMed ID: 7951120
    [Abstract] [Full Text] [Related]

  • 38. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Román J, Serrano J, Jiménez A, Castillejo JA, Reina ML, González MG, Rodríguez MC, García I, Sánchez J, Maldonado J, Torres A.
    Haematologica; 2000 Feb 11; 85(2):173-80. PubMed ID: 10681725
    [Abstract] [Full Text] [Related]

  • 39. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
    Saito T, Kanda Y, Kami M, Kato K, Shoji N, Kanai S, Ohnishi T, Kawano Y, Nakai K, Ogasawara T, Matsubara H, Makimoto A, Tanosaki R, Tobinai K, Wakasugi H, Takaue Y, Mineishi S.
    Clin Cancer Res; 2002 Apr 11; 8(4):1014-20. PubMed ID: 11948108
    [Abstract] [Full Text] [Related]

  • 40. Prolonged remission of accelerated phase Philadelphia chromosome negative chronic myeloid leukemia following autologous recovery of normal hematopoietic elements after busulfan/cyclophosphamide and allogeneic marrow transplantation.
    Kapoor N, Keever CA, Hsu SH, Copelan EA, Tutschka PJ.
    Bone Marrow Transplant; 1992 Feb 11; 9(2):143-5. PubMed ID: 1349249
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.